Compare Revvity Inc (RVTY) vs Toro Company (The) Common Stock (TTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Toro Company (The) Common Stock — how do they compare? Revvity Inc trades at $151.84 (market cap $17.30B), while Toro Company (The) Common Stock trades at $98.27 (market cap $9.27B). The key difference: Revvity Inc is the larger of the two by market cap, and Toro Company (The) Common Stock pays the higher dividend (1.59%). Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 13 Days and Toro Company (The) Common Stock for 0 Days on average.
| RVTY | TTC | |
|---|---|---|
Market Cap | $17.30B | $9.27B |
Volume | 1,387,588 | 688,325 |
Sector | Health | Industrials |
52-Week High | $157.36 | $101.76 |
52-Week Low | $82.26 | $67.99 |
Typical Hold Time | 13 Days | 0 Days |
Enterprise Value | $19.62B | $10.17B |
Dividend Yield | 0.18% | 1.59% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $155.08, down 0.34% on the day but near its 52-week high of $158.28. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. The company maintains solid profitability with 54.98% gross margins and positive cash flow trends.
RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics (P/E 74.56) require careful consideration. Near-term catalysts include Q3 earnings on November 3, 2026, while risks involve China market pressures and margin compression. Analyst consensus leans bullish with 52% buy ratings and a $132.13 price target, suggesting potential downside from current levels despite positive momentum.
Toro Company (TTC) trades at $97.88, up 1.27% with strong technical momentum above its 50-day moving average. The company demonstrates solid fundamentals with consistent earnings beats, including Q2 2026 EPS of $1.33 beating expectations of $1.31, and raised full-year guidance. Revenue growth of 8.4% in Q3 2026 to $1.23 billion reflects robust demand across professional and residential segments, supported by infrastructure and automation initiatives under new CEO leadership.
Toro presents a balanced investment case with 36% analyst buy ratings and $117.50 price target suggesting 20% upside. However, execution risks from inflation, tariffs, and competitive pressures warrant caution. The stock's premium valuation (P/E 26.17) requires sustained earnings growth, making Q3 2026 results critical for validating current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Toro Company (The) Common Stock
The Toro Company designs, manufactures, and markets equipment for turf maintenance, snow and ice management, landscaping, construction, and irrigation. Its products serve golf courses, sports fields, and residential and commercial properties in more than 125 countries.
Read more on TTC →
